XML 41 R29.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue from Contracts with Customers (Tables)
9 Months Ended
Sep. 30, 2025
Revenue from Contracts with Customers  
Schedule of product revenue provision and allowance categories

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance as of December 31, 2024

$

191,508

$

147,134

$

38,512

Provision related to current period sales

361,674

51,576

157,390

Ironshore measurement period adjustments

616

(23,843)

7

Changes in estimate related to prior period sales

(3,934)

(4,878)

288

Credits/payments made

(380,173)

(30,072)

(167,517)

Balance as of September 30, 2025

$

169,691

$

139,917

$

28,680

    

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance as of December 31, 2023

$

149,826

$

77,505

$

20,917

Provision related to current period sales

303,570

33,587

124,194

Acquired from Ironshore

42,515

36,588

5,011

Changes in estimate related to prior period sales

(1,634)

2,419

(85)

Credits/payments made

(296,433)

(34,069)

(120,611)

Balance as of September 30, 2024

$

197,844

$

116,030

$

29,426

(1)Provisions for rebates and incentives include managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets.
(2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets.
(3)Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s Condensed Consolidated Balance Sheets.
Schedule of disaggregation of revenue

Three Months Ended September 30,

Nine Months Ended September 30,

2025

2024

2025

2024

Belbuca

$

58,255

$

53,197

$

162,513

$

156,058

Xtampza ER

50,478

    

49,492

150,725

139,876

Jornay PM

41,802

7,961

102,967

7,961

Nucynta IR

31,988

25,361

85,906

76,524

Nucynta ER

22,813

19,773

62,445

58,231

Symproic

4,025

3,517

10,562

10,850

Total product revenues, net

$

209,361

$

159,301

$

575,118

$

449,500